Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nizatidine for Olanzapine-Induced Weight Gain in Schizophrenia
NCT00486005Phase 4
Key facts
- Status
- Completed
- Start
- Feb 2003
- Countries
- 1
- Sponsor
- Eli Lilly and Company
- Modality
- Small Molecules
- Drugs
- nizatidine
01
Overview
Phase 4, randomised, double-blind trial comparing Nizatidine + Olanzapine with Placebo + Olanzapine (2 arms). Primary endpoint: Weight Gain. Started Feb 2003; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Nizatidine + Olanzapine
Nizatidine added to ongoing Olanzapine therapy
Placebo + Olanzapine
Placebo added to ongoing Olanzapine therapy
03
Who it enrols
Patients with schizophrenia aged 18-65 who have been on olanzapine (5-20 mg/day) for 2-6 months and have experienced at least a 5% weight gain.
04
Endpoints
Primary
Weight Gain
Secondary
Cognitive Control of Appetite
Brief Psychiatric Rating Scale
Adverse Events
Vital Signs
Laboratory Results
Extrapyramidal Symptoms
Beyond the preview
Go deeper on NCT00486005.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00486005.